FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

Home
/
update
/
details

10x Genomics Technology Backs Garvan Institute’s TenK10K Project to Revolutionize Complex Disease Treatment

NextEdge Admin

06 Aug 2024

2 min 24 sec

10x Genomics, a leader in single cell and spatial biology, announced its involvement in TenK10K, a large-scale study by the Garvan Institute of Medical Research. TenK10K aims to map 50 million human cells from 10,000 individuals to uncover genomic fingerprints of autoimmune diseases, heart diseases, and cancer. The Garvan Institute selected Chromium GEM-X products from 10x Genomics for single cell data generation to enhance disease risk prediction and treatment response.

Professor Joseph Powell, TenK10K project leader, emphasized the potential of single cell sequencing to reveal unique cell fingerprints, offering new translational opportunities through advanced machine learning methods. The project aims to develop commercial tests for autoimmune diseases, trials for RNA therapies, early treatment targets for cancers and long COVID, and tests to monitor heart attack aftermath and sudden death risks.

Chromium GEM-X products, known for their increased sensitivity, throughput, and data quality, will be used in the study. Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics, highlighted the potential impact of large-scale single cell analysis on understanding, diagnosing, and treating diseases. The project builds on the Garvan Institute's OneK1K study, which analyzed over one million cells from 1,000 people and led to a clinical trial in Sydney hospitals to match patients with effective treatments.

In partnership with Illumina, the Garvan Institute will receive supplies, equipment, and research support. 10x Genomics continues to drive innovation in single cell and spatial biology, supporting breakthroughs in oncology, immunology, neuroscience, and more.